340B 'Penny Pricing' Policy Draws Manufacturers' Ire
This article was originally published in The Pink Sheet Daily
Manufacturers pinpoint flaws in and outline alternatives to HRSA's plan to codify the now non-binding policy of charging a penny per pill for certain products. Concerns are raised about stockpiling and drug diversion, in addition to fair payment.
You may also be interested in...
HRSA proposes another delay to effective date of final rule on calculating the ceiling prices for drugs sold to 340B program. Agency also appears ready to reconsider the 'penny pricing' policy that rule would codify.
Proposed rule would implement how civil monetary penalties will be applied to manufacturers that “knowingly and intentionally” deny 340B prices to eligible health care providers.
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.